Edison issues research update on Abzena (ABZA)

London, UK, 14 September 2016

Edison issues research update on Abzena (ABZA)

Abzena announced a strong business update including a twelfth Abzena inside product entering Phase I clinical development and positive momentum in trading. This continues to underpin the rationale behind expanding the company to provide a broader range of services. We now use an estimated H117 cash position, which decreases the valuation slightly to £140m, offset slightly by the twelfth Abzena inside product.

We have slightly decreased our valuation to £140m (vs £143m) or 102p per share (vs 104p). This is primarily due to updating our estimated H117 cash position of £9.6m (vs £13.7m). We have also included the twelfth Abzena inside product entering Phase I clinical development, which adds $1.7m to our rNPV. We assume similar parameters to previous Abzena inside products in Phase I: peak sales of $750m, 1% royalty, launch in 2023 and a 15% probability of success. Abzena continues to demonstrate the potential in its integrated service offering and we expect potential uplifts to valuation as its Abzena inside products progress towards commercialisation, most notably GS-5745 in gastric cancer (Phase III).

Click here to view the full report

All reports published by Edison are available to download free of charge from its website: www.edisoninvestmentresearch.com

About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison on: